Janney Montgomery Scott set a $125.00 target price on bluebird bio, Inc. (NASDAQ:BLUE) in a research note issued to investors on Monday morning. The firm currently has a buy rating on the biotechnology company’s stock.
Several other research analysts have also recently weighed in on the stock. Cantor Fitzgerald set a $39.00 price target on shares of bluebird bio and gave the company a sell rating in a research report on Saturday. Cowen and Company reissued a buy rating on shares of bluebird bio in a research report on Friday. Wedbush reissued an outperform rating and set a $100.00 price target (down previously from $121.00) on shares of bluebird bio in a research report on Friday. BidaskClub raised shares of bluebird bio from a buy rating to a strong-buy rating in a research report on Friday. Finally, Standpoint Research reaffirmed a reduce rating and issued a $110.00 target price on shares of bluebird bio in a research report on Friday, June 16th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $95.03.
bluebird bio (NASDAQ BLUE) traded down 3.78% during midday trading on Monday, hitting $106.90. 1,297,578 shares of the stock traded hands. The stock has a 50-day moving average of $92.89 and a 200 day moving average of $81.98. The firm’s market cap is $4.38 billion. bluebird bio has a 52-week low of $36.62 and a 52-week high of $120.95.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($1.68) earnings per share for the quarter, beating the consensus estimate of ($1.76) by $0.08. The firm had revenue of $6.83 million for the quarter, compared to analysts’ expectations of $1.51 million. bluebird bio had a negative net margin of 2,402.03% and a negative return on equity of 35.17%. Equities analysts forecast that bluebird bio will post ($6.64) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “bluebird bio, Inc. (BLUE) Given a $125.00 Price Target by Janney Montgomery Scott Analysts” was first posted by sleekmoney and is the property of of sleekmoney. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://sleekmoney.com/bluebird-bio-inc-blue-given-a-125-00-price-target-by-janney-montgomery-scott-analysts/1944409.html.
In related news, insider Jason Cole sold 17,245 shares of the company’s stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $100.22, for a total transaction of $1,728,293.90. Following the sale, the insider now directly owns 30,871 shares in the company, valued at $3,093,891.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel Lynch sold 2,500 shares of the company’s stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $120.03, for a total transaction of $300,075.00. Following the sale, the director now owns 5,300 shares in the company, valued at $636,159. The disclosure for this sale can be found here. Insiders have sold 33,758 shares of company stock worth $3,298,951 over the last 90 days. Insiders own 3.90% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can raised its stake in bluebird bio by 28.5% in the first quarter. Great West Life Assurance Co. Can now owns 4,509 shares of the biotechnology company’s stock worth $409,000 after buying an additional 1,000 shares during the last quarter. Reynders McVeigh Capital Management LLC raised its stake in bluebird bio by 40.3% in the first quarter. Reynders McVeigh Capital Management LLC now owns 7,535 shares of the biotechnology company’s stock worth $685,000 after buying an additional 2,165 shares during the last quarter. Russell Investments Group Ltd. raised its stake in bluebird bio by 42.1% in the first quarter. Russell Investments Group Ltd. now owns 33,823 shares of the biotechnology company’s stock worth $3,074,000 after buying an additional 10,027 shares during the last quarter. Strs Ohio raised its stake in bluebird bio by 40.5% in the first quarter. Strs Ohio now owns 5,900 shares of the biotechnology company’s stock worth $536,000 after buying an additional 1,700 shares during the last quarter. Finally, First Mercantile Trust Co. raised its stake in bluebird bio by 14.4% in the first quarter. First Mercantile Trust Co. now owns 2,897 shares of the biotechnology company’s stock worth $263,000 after buying an additional 365 shares during the last quarter.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/bluebird-bio-inc-blue-given-a-125-00-price-target-by-janney-montgomery-scott-analysts/1944409.html
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.